RM O'Bryan, LH Baker, JE Gottlieb, SE Rivkin, … - CA A Cancer Journal … - interscience.wiley.com Because patients treated with 60-90 mg/m 2 every three to four weeks reach cardiotoxic doses
of 550 mg/m 2 within 36 weeks, prolonged treatment with Adriamycin is limited. The purpose
of this study was to determine whether lower doses could be given over longer periods ... Cited by 249 - Related articles - All 2 versions
L Lenaz, JA Page - Cancer treatment reviews, 1976 - ncbi.nlm.nih.gov 1: Cancer Treat Rev. 1976 Sep;3(3):111-20. Cardiotoxicity of adriamycin and related
anthracyclines. Lenaz L, Page JA. Mesh Terms: Animals; Arrhythmias, Cardiac/chemically induced;
Chick Embryo; Cricetinae; Daunorubicin/toxicity*; Dogs; Doxorubicin/toxicity*; ... Cited by 235 - Related articles - All 2 versions
RA Minow, RS Benjamin, ET Lee, JA … - CA A Cancer Journal for … - interscience.wiley.com The records of 53 patients treated with Adriamycin, 17 of whom developed congestive heart failure
and 36 of whom received a similar total dose of Adriamycin without developing congestive heart
failure, were analyzed for factors associated with Adriamycin cardiomyopathy. The risk of ... Cited by 215 - Related articles - All 2 versions
SE Jones, BGM Durie, SE Salmon - CA A Cancer Journal for Clinicians - interscience.wiley.com Fifty-five consecutive women with advanced breast cancer were treated with a combination of
adriamycin (40 mg/m 2 administered intravenously on day 1) and cyclophosphamide (200
mg/m 2 /day given orally in divided doses for 4 days on days 3-6). Courses were repeated ... Cited by 133 - Related articles - All 2 versions
AC Gilladoga, C Manuel, CTC Tan, N Wollner, … - CA A Cancer Journal … - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 90 - Related articles - All 2 versions
JS Steinberg, AJ Cohen, AG Wasserman, P … - CA A Cancer Journal … - interscience.wiley.com The magnitude of acute arrhythmogenicity of doxorubicin administration has not been
characterized. In this study the type and frequency of cardiac arrhythmia is determined in the
first hour and first 24 hours following doxorubicin given as a 10-minute infusion. ... Cited by 83 - Related articles - All 3 versions
- ►aacrjournals.org [PDF] JW Cowens, PJ Creaven, WR Greco, DE Brenner, Y … - Cancer Research, 1993 - AACR 90 mg/m2 every 3 weeks and daily for 3 days at doses of 20, 25, and 30 ing/nr'/da\. The
dose-limiting toxicity was leucopenia: the maximum tol erated doses were one at 90 mg/m2 and
three at 25 mg/nWday. Nausea, vomiting, and stomatitis were minimal or absent at each ... Cited by 79 - Related articles - BL Direct - All 3 versions
- ►bloodjournal.org [PDF] SE Sallan, BM Cammita, JR Cassady, DG Nathan, E … - Blood, 1978 - Am Soc Hematology . Hematology; all rights reserved Copyright 2007 by The American Society of DC 20036. by the
American Society of Hematology, 1900 M St, NW, Suite 200, Washington Blood (print ISSN
0006-4971, online ISSN 1528-0020), is published semimonthly ... For personal use only. ... Cited by 77 - Related articles - All 3 versions
BA Mills, RW Roberts - Cancer, 1979 - ncbi.nlm.nih.gov Fatal cardiomyopathy developed in two patients receiving cyclophosphamide in preparation
for bone marrow transplantation. Both patients had normal EKGs prior to receiving cyclophosphamide
in total doses of 168 mg/kg (case 1) and 144 mg/kg (case 2) and subsequently developed ... Cited by 76 - Related articles
MR Bristow, MB Lopez, JW Mason, ME … - CA A Cancer Journal … - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 66 - Related articles - All 2 versions
